Unicycive Therapeutics, Inc., a biotechnology company headquartered in Los Altos, United States, has been making strides in the healthcare sector with its focus on developing innovative therapies. The company is primarily engaged in the research and development of two novel treatments aimed at addressing hyperphosphatemia in patients suffering from chronic kidney disease (CKD) and acute kidney injury (AKI).
As of September 1, 2026, Unicycive Therapeutics’ stock was trading at a close price of $5.19 on the Nasdaq exchange. The company’s market capitalization stood at approximately $140.67 million, reflecting its position within the biotechnology industry. Over the past year, the stock has experienced significant volatility, with a 52-week high of $8.74 recorded on May 13, 2026, and a 52-week low of $3.71 on September 24, 2025.
The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -3.26, suggesting that it is not currently generating profits. This is not uncommon for biotechnology firms, particularly those in the development phase of their pipeline, as substantial investments are often required for research and clinical trials before any revenue is realized.
Unicycive Therapeutics’ strategic focus on hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, is particularly relevant for patients with CKD and AKI. These conditions often lead to complications due to phosphate imbalance, and current treatment options are limited. By targeting this unmet medical need, Unicycive aims to improve patient outcomes and potentially capture a significant share of the market.
The company’s efforts are centered around advancing its pipeline through rigorous clinical trials, with the goal of demonstrating the safety and efficacy of its therapies. Success in these trials could pave the way for regulatory approval and commercialization, offering new hope for patients and potentially enhancing the company’s financial performance.
In summary, Unicycive Therapeutics, Inc. is a biotechnology firm dedicated to developing groundbreaking treatments for hyperphosphatemia in CKD and AKI patients. Despite its current lack of profitability, the company’s focus on addressing a critical healthcare need positions it as a noteworthy player in the biotechnology sector. As it progresses through clinical trials, stakeholders will be closely monitoring its developments, anticipating the potential impact on both patient care and the company’s market valuation.
